Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Denise Pettit

Physician Assistant, Medical Martinsburg, WV Physician Assistant

NPI 1669497152 CMS profile 11025991

101 Marcley Drive, Martinsburg, WV 25401

Open in the dashboard

General payments

$5,688

319 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Denise Pettit of Martinsburg, WV is reported in the CMS Open Payments database as having received $5,688 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,488 73
2024 General $1,442 76
2023 General $1,152 69
2022 General $803 45
2021 General $803 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Denise Pettit
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Denise Pettit were reported at $1,488. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Denise Pettit Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $803 $156 $41–$563 $132
2022 $803 $185 $55–$649 $149
2023 $1,152 $199 $58–$717 $160
2024 $1,442 $206 $62–$740 $164
2025 $1,488 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,247 75 payments
  2. Lilly USA, LLC $1,140 67 payments
  3. AstraZeneca Pharmaceuticals LP $576 31 payments
  4. GlaxoSmithKline, LLC. $366 16 payments
  5. Astellas Pharma US Inc $333 16 payments
  6. Pfizer Inc. $252 16 payments
  7. Novo Nordisk Inc $237 15 payments
  8. Amgen Inc. $206 11 payments
  9. Otsuka America Pharmaceutical, Inc. $135 9 payments
  10. Exact Sciences Corporation $135 5 payments
  11. Other $1,060 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,680 318 payments
  2. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $756 47 payments
  2. JARDIANCE $730 39 payments
  3. MOUNJARO $410 28 payments
  4. FARXIGA $374 20 payments
  5. Veozah $276 13 payments
  6. QULIPTA $233 13 payments
  7. UBRELVY $220 14 payments
  8. TRELEGY ELLIPTA $191 10 payments
  9. ZEPBOUND $175 11 payments
  10. VRAYLAR Neuroscience $169 8 payments
  11. Other $3,344 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,234

Median for Physician Assistant: 241

Drug cost

$275,064

Median for Physician Assistant: $4,110

Branded share of claims

19.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 54 $76,524
Mounjaro Tirzepatide Brand 38 $59,489
Jardiance Empagliflozin Brand 41 $43,912
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $31,768
Vraylar Cariprazine Hcl Brand 13 $18,104
Farxiga Dapagliflozin Propanediol Brand 11 $11,025
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $8,672
Symbicort Budesonide/Formoterol Fumarate Brand 12 $2,815
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $1,513
Metoprolol Succinate Generic 109 $1,284

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$28,152

Of which drugs: $1,772

Medicare patients

184

Average age 73

Services billed

557

113 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 34%
Chronic kidney disease 28%
Ischemic heart disease 22%
COPD 18%
Depression 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $284
$284 13 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $156
$156 11 —
JARDIANCE
  • Lilly USA, LLC $137
$138 41 —
MOUNJARO
  • Lilly USA, LLC $113
$113 38 —
Veozah
  • Astellas Pharma US Inc $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record